Vaxart Publishes Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study

 Study demonstrates oral vaccination significantly reduces viral titers in the lung and protects against COVID-19 in animal model

Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vaxart’s COVID-19 oral vaccine candidate’s potential efficacy in preventing SARS-CoV-2 infection.

“The complete data from the Hamster Challenge Study, together with Vaxart’s other preclinical and clinical data, reinforce our belief that Vaxart’s vaccine could have a major impact on the fight against COVID-19.” said Dr. Sean Tucker, Vaxart’s Chief Scientific Officer and founder, as well as a co-author of the study.

The Hamster Challenge Study adds to the significant body of preclinical and clinical evidence Vaxart has amassed during the last two years supporting its belief that Vaxart’s room temperature oral tablet COVID-19 vaccine candidate, can be effective against SARS-CoV-2:

• A Hamster Transmission Study, conducted by Duke University and published in bioRxiv last month, demonstrated that the COVID-19 vaccine reduced the airborne transmission of SARS-CoV-2 virus in a hamster model.

• These results are consistent with those from Vaxart's Phase II human flu challenge study, which showed that Vaxart's oral tablet flu vaccine was better at reducing shedding than the injectable flu vaccine comparator.

• Vaxart’s Phase I results, released earlier this year, showed that the vaccine triggered multiple immune responses against SARS-CoV-2 antigens, including strong T-cell and IgA responses.

• Vaxart anticipates its Phase II clinical study to provide additional evidence regarding the potential impact and efficacy of the oral tablet COVID-19 vaccine. Initial data from that study is expected in Q1 2022.

https://finance.yahoo.com/news/vaxart-announces-publication-complete-data-130000568.html